Key facts
- Third Pole Therapeutics’s last known valuation is $240.0M (Mar 2025).
- It has raised $125.8M; the latest was Later Stage VC ($16.9M) in Mar 2025.
- Notable investors include National Institutes of Health, Johnson & Johnson Innovation - JLABS, Acorn Campus Taiwan, Lung, Michael Marsh — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Third Pole Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Third Pole Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Third Pole Therapeutics
Developer of a medical inhalation device designed to offer life-saving cardiopulmonary therapies. The company's device serves as the current standard of care to treat hypoxic respiratory failure in newborns, as it is capable of generating nitric oxide from air and electricity on-demand and on-site which potentially eliminates the need for large compressed gas cylinders, enabling clinicians to acquire flexible and innovative options in therapeutic fields beyond hypoxic respiratory failure, including pulmonary hypertension, interstitial lung disease, and chronic obstructive pulmonary disease.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2014
- Employees
- 31
- Website
- pole3.com/
- Ownership
- Privately Held (backing)
Third Pole Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Third Pole Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Third Pole Therapeutics in its N-PORT filings yet. We sweep new filings monthly.